Get started
Author

Y Wang

Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA–a retrospective study of claims data from 2009 to 2020
2021 · J. F. Merola, N. Dennis, et al. · Clinical Rheumatology · 24
A108 Ustekinumab Iv Induction Results in Crohn’s Disease Symptom Improvement Within the First Week in Anti-tnf Refractory Patients
2018 · W Sandborn, B Yeager, et al. · Journal of the Canadian Association of Gastroenterology · 3
PDF
P347 New-onset autoimmune disorders, primarily psoriasis, in anti-TNF biologic exposed paediatric patients: the DEVELOP experience
2019 · G Veereman, A Griffiths, et al. · Journal of Crohn s and Colitis · 1
P115 Ustekinumab in DEVELOP: A safety analysis from an Inflammatory Bowel Disease multicenter, prospective, long-term registry of paediatric patients
2024 · S Koletzko, G Veereman, et al. · Journal of Crohn s and Colitis
PDF
P375 A simulation study to evaluate the performance of a multiple imputation method to address missing data in an analysis of clinical effectiveness using the ImproveCareNow Registry of pediatric patients with Crohn’s disease
2021 · N Zhang, C Liu, et al. · Journal of Crohn s and Colitis
P382 Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience
2019 · J Escher, B Gold, et al. · Journal of Crohn s and Colitis
P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience
2019 · H Winter, J Izanec, et al. · Journal of Crohn s and Colitis
P446 Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience
2019 · J Escher, M Dubinsky, et al. · Journal of Crohn s and Colitis
Works count: 8
Citation count: 28
H-index: 2
I10-index: 1
Year
Topic
Type